Esya Labs
Esya Labs is a biotech startup specializing in brain health diagnostics and biomarker discovery for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company leverages patented DNA nanotechnology, intracellular multi-omics analytics, and AI-driven bioinformatics to develop ultra-sensitive assays and diagnostic platforms. Their flagship technology includes DNA nanoprobes and the NULISA proteomics platform, developed in partnership with Alamar Biosciences, offering femtogram-level sensitivity and high multiplexing for biomarker validation and drug development support. Esya Labs operates under GLP and CLIA standards, targeting biopharma, biotech, and clinical research markets, with a focus on early diagnosis, patient stratification, and precision medicine. The company is based in London, UK, and the US, and was spun out from the University of Chicago. Their team includes experts in chemistry, cell biology, and computational biology, supported by notable advisors including a Nobel laureate. Esya Labs aims to set a new global standard in brain health by integrating biomarker analysis with deep learning to transform drug discovery and patient care.
Esya Labs
Esya Labs is a biotech startup specializing in brain health diagnostics and biomarker discovery for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company leverages patented DNA nanotechnology, intracellular multi-omics analytics, and AI-driven bioinformatics to develop ultra-sensitive assays and diagnostic platforms. Their flagship technology includes DNA nanoprobes and the NULISA proteomics platform, developed in partnership with Alamar Biosciences, offering femtogram-level sensitivity and high multiplexing for biomarker validation and drug development support. Esya Labs operates under GLP and CLIA standards, targeting biopharma, biotech, and clinical research markets, with a focus on early diagnosis, patient stratification, and precision medicine. The company is based in London, UK, and the US, and was spun out from the University of Chicago. Their team includes experts in chemistry, cell biology, and computational biology, supported by notable advisors including a Nobel laureate. Esya Labs aims to set a new global standard in brain health by integrating biomarker analysis with deep learning to transform drug discovery and patient care.
TL;DR
Primary focus: DNA-nanoprobe diagnostics and multi-omics biomarker platforms for neurodegenerative diseases
Flagship tech: DNA nanoprobes and NULISA proteomics platform (high-sensitivity, femtogram-level)
Markets: Biopharma, biotech, clinical research (biomarker validation, drug development support)
Geography: Based in London, UK and Frisco/Dallas, Texas, USA
Dhivya Venkat (CEO) and Prof. Yamuna Krishnan (CSO)
